View Financial HealthChengDa Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 1/6ChengDa Pharmaceuticals 은(는) 현재 수익률이 0.59% 인 배당금 지급 회사입니다.핵심 정보0.6%배당 수익률0.007%자사주 매입 수익률총 주주 수익률0.6%미래 배당 수익률n/a배당 성장률-8.2%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향-859%최근 배당 및 자사주 매입 업데이트Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.모든 업데이트 보기Recent updatesBoard Change • May 20High number of new directorsIndependent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025.공시 • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026공시 • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025공시 • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025공시 • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 37% over the past year.공시 • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China.Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China.공시 • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.공시 • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).Board Change • Mar 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ping Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 301201 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.배당금 증가: 301201 4 년 동안만 배당금을 지급해 왔으며 그 이후 지급액이 감소했습니다.배당 수익률 vs 시장ChengDa Pharmaceuticals 배당 수익률 vs 시장301201의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (301201)0.6%시장 하위 25% (CN)0.4%시장 상위 25% (CN)2.1%업계 평균 (Pharmaceuticals)2.2%분석가 예측 (301201) (최대 3년)n/a주목할만한 배당금: 301201 의 배당금( 0.59% )은 CN 시장에서 배당금 지급자의 하위 25%( 0.38% )보다 높습니다.고배당: 301201 의 배당금( 0.59% )은 CN 시장에서 배당금 지급자의 상위 25%( 2.14% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 301201 배당금을 지급하고 있지만 회사는 수익성이 없습니다.주주 현금 배당현금 흐름 범위: 301201 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 02:25종가2026/06/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChengDa Pharmaceuticals Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.
Board Change • May 20High number of new directorsIndependent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025.
공시 • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
공시 • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.
공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
공시 • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
공시 • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.
공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.
Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).
Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 37% over the past year.
공시 • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China.
Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China.
공시 • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).
공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.
공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.
공시 • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.
Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).
Board Change • Mar 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ping Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.